Gain Therapeutics (GANX) Registration Filing summary

Company overview and business model

• Focuses on developing novel small molecule therapeutics for CNS disorders, lysosomal storage disorders, metabolic disorders, and oncology through protein degradation approaches.

• Lead candidate GT-02287 targets Parkinson's disease and is in Phase 1b clinical trials, with promising safety and efficacy data.

• Utilizes the proprietary Magellan™ computational platform to identify allosteric binding sites and design highly specific small molecules.

• Pipeline is disease-agnostic, enabling expansion into multiple therapeutic areas and collaborations with industry and academia.

Financial performance and metrics

• As of November 3, 2025, 36,241,000 shares of common stock outstanding; no preferred stock outstanding.

• Common stock last traded at $1.90 per share on November 6, 2025, on Nasdaq under the symbol GANX.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used for working capital and general corporate purposes.

• Pending use, proceeds will be invested in short-term, interest-bearing or investment-grade securities.